Wanbury Limited (WANBURY) receives 9 'No DMF Deficiency' letters from USFDA, expands Metformin business in Saudi Arabia and Mexico.
Wanbury Limited launches berrysoft™ baby product range, marking strategic entry in paediatric dermatology segment with GST registrations and drug licenses.
Wanbury Limited (WANBURY) announced FY26 results with 117% YoY PAT growth, EPS doubling, and new API launches.